Use and outcomes of anticoagulants for the treatment and prevention of thrombosis among hospitalized patients
抗凝药在治疗和预防住院患者血栓形成中的使用和结果
基本信息
- 批准号:10210290
- 负责人:
- 金额:$ 12.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-07-01 至 2023-06-30
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAdherenceAdverse eventAnticoagulant therapyAnticoagulantsAnticoagulationAspirinAtrial FibrillationAwardCaliforniaCardiovascular systemChronicClinicalClinical ResearchComplexDataDoseEnvironmentEpidemiologyFacultyGoalsHealth systemHemorrhageHospitalsInterruptionKneeMedicineMentorsMonitorMorbidity - disease rateOperative Surgical ProceduresOralOutcomeOutcomes ResearchOutcomes and Health Services ResearchPatient Outcomes AssessmentsPatient Self-ReportPatient-Focused OutcomesPatientsPerioperativePharmaceutical PreparationsPharmacologyPostoperative HemorrhagePostoperative PeriodPrevalencePreventionPrevention strategyProceduresProphylactic treatmentQuality of lifeRecording of previous eventsReplacement ArthroplastyResearchResearch PersonnelResearch TrainingRiskSan FranciscoStroke preventionSurveysTherapeuticThromboembolismThrombosisTimeTime trendTrainingUnited StatesUniversitiesVitamin KWarfarinbasecareerclinical practicecosthealth related quality of lifehigh riskhip replacement arthroplastyhip surgeryinsightknee replacement arthroplastymedication compliancemortalityolder patientpatient orientedpreventprogramssatisfactiontrendvenous thromboembolism
项目摘要
ABSTRACT
More than 2 – 3 million people are prescribed anticoagulants every year in the United States for the treatment
and prevention of thromboembolic conditions. Used for indications ranging from stroke-prevention in atrial
fibrillation to the acute treatment of venous thromboembolism, anticoagulants can significantly reduce the
morbidity and mortality related to thromboembolism. However, anticoagulants are also associated with
significant risks of bleeding, as well as costs and burden to patients. The overall objective of this proposal is to
gain greater insight into the optimal use of anticoagulants in different clinical situations, with the ultimate goal
being to maximize their benefits and minimize their risks. The other over-arching goal of the proposal is to
allow Dr. Fang to build upon a successful history of mentoring trainees and faculty in order to develop a
research and mentoring program geared towards training junior investigators preparing for careers in patient-
oriented cardiovascular outcomes research.
The research aims of this proposal will address the contemporary use of pharmacologic prevention strategies
to prevent venous thromboembolism after joint replacement surgery, describe trends in the periprocedural
management and outcomes of patients who need to interrupt chronic anticoagulant therapy in order to undergo
elective surgery, and examine the association between anticoagulant treatment satisfaction, health-related
quality-of-life, and medication adherence in people taking oral anticoagulants. These aims will help inform the
appropriate use of anticoagulants in clinical practice.
As a hospital-based clinician investigator, Dr. Fang serves as the Research Director for the University of
California, San Francisco (UCSF) Division of Hospital Medicine. Her research program is based in the
outstanding clinical, training, and research environment of UCSF. The aims of this proposal will support her
efforts in developing cardiovascular outcomes researchers, as well as strengthen the capacity that her
research platform has to support mentee research.
抽象的
在美国,每年有超过 2-300 万人接受抗凝药物治疗
用于预防心房中风等适应症。
颤动静脉血栓栓塞的急性治疗,抗凝药物可显着降低
然而,抗凝剂也与血栓栓塞相关。
出血的重大风险以及患者的费用和负担 该提案的总体目标是
更深入地了解不同临床情况下抗凝剂的最佳使用,以实现最终目标
该提案的另一个总体目标是最大化他们的利益并最小化他们的风险。
让方博士能够在指导学员和教师的成功历史的基础上发展
研究和指导计划旨在培训初级研究人员为患者职业生涯做好准备
面向心血管结果的研究。
该提案的研究目的将解决药物预防策略的当代使用
为了预防关节置换手术后静脉血栓栓塞,描述围手术期的趋势
需要中断长期抗凝治疗以接受治疗的患者的管理和结果
择期手术,并检查抗凝治疗满意度与健康相关之间的关系
这些目标将有助于告知服用口服抗凝剂的人的生活质量和药物依从性。
临床实践中合理使用抗凝药物。
作为一名医院临床医生研究员,方博士担任英国大学的研究主任
加利福尼亚州旧金山 (UCSF) 医院医学部 她的研究项目位于
加州大学旧金山分校出色的临床、培训和研究环境将支持她。
心血管结果研究人员的发展,以及努力和加强她的能力
研究平台必须支持受训者的研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARGARET C. FANG其他文献
MARGARET C. FANG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARGARET C. FANG', 18)}}的其他基金
Supplement to Direct-Acting Oral Anticoagulants: Anticoagulant Activity in Understudied Older NVAF Patients
直接作用口服抗凝剂的补充:正在研究的老年 NVAF 患者的抗凝活性
- 批准号:
10297780 - 财政年份:2020
- 资助金额:
$ 12.18万 - 项目类别:
Use and outcomes of anticoagulants for the treatment and prevention of thrombosis among hospitalized patients
抗凝药在治疗和预防住院患者血栓形成中的使用和结果
- 批准号:
10456273 - 财政年份:2018
- 资助金额:
$ 12.18万 - 项目类别:
Anticoagulation Treatment and Long-Term Outcomes After Venous Thromboembolism
静脉血栓栓塞后的抗凝治疗和长期结果
- 批准号:
7947651 - 财政年份:2010
- 资助金额:
$ 12.18万 - 项目类别:
Anticoagulation Treatment and Long-Term Outcomes After Venous Thromboembolism
静脉血栓栓塞后的抗凝治疗和长期结果
- 批准号:
8476262 - 财政年份:2010
- 资助金额:
$ 12.18万 - 项目类别:
Anticoagulation Treatment and Long-Term Outcomes After Venous Thromboembolism
静脉血栓栓塞后的抗凝治疗和长期结果
- 批准号:
8669067 - 财政年份:2010
- 资助金额:
$ 12.18万 - 项目类别:
Anticoagulation Treatment and Long-Term Outcomes After Venous Thromboembolism
静脉血栓栓塞后的抗凝治疗和长期结果
- 批准号:
8133874 - 财政年份:2010
- 资助金额:
$ 12.18万 - 项目类别:
Anticoagulation Treatment and Long-Term Outcomes After Venous Thromboembolism
静脉血栓栓塞后的抗凝治疗和长期结果
- 批准号:
8280382 - 财政年份:2010
- 资助金额:
$ 12.18万 - 项目类别:
Risks of Warfarin for Elders with Atrial Fibrillation
华法林对患有心房颤动的老年人的风险
- 批准号:
7151712 - 财政年份:2006
- 资助金额:
$ 12.18万 - 项目类别:
Risks of Warfarin for Elders with Atrial Fibrillation
华法林对患有心房颤动的老年人的风险
- 批准号:
7486758 - 财政年份:2006
- 资助金额:
$ 12.18万 - 项目类别:
Risks of Warfarin for Elders with Atrial Fibrillation
华法林对患有心房颤动的老年人的风险
- 批准号:
7894564 - 财政年份:2006
- 资助金额:
$ 12.18万 - 项目类别:
相似国自然基金
时空序列驱动的神经形态视觉目标识别算法研究
- 批准号:61906126
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
本体驱动的地址数据空间语义建模与地址匹配方法
- 批准号:41901325
- 批准年份:2019
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
- 批准号:61802133
- 批准年份:2018
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
针对内存攻击对象的内存安全防御技术研究
- 批准号:61802432
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
- 批准号:61872252
- 批准年份:2018
- 资助金额:64.0 万元
- 项目类别:面上项目
相似海外基金
2/2 Multi-Center CLEAN AIR 2 Randomized Control Trial in COPD
2/2 慢性阻塞性肺病多中心 CLEAN AIR 2 随机对照试验
- 批准号:
10722232 - 财政年份:2023
- 资助金额:
$ 12.18万 - 项目类别:
Michigan Emergency Department Improvement Collaborative AltERnaTives to admission for Pulmonary Embolism (MEDIC ALERT PE) Study
密歇根急诊科改进合作入院肺栓塞 (MEDIC ALERT PE) 研究
- 批准号:
10584217 - 财政年份:2023
- 资助金额:
$ 12.18万 - 项目类别:
A Randomized Pilot and Feasibility Study of a cultuRE-Directed approach to Urinary traCT Infection symptoms in older womeN: a mixed methods evaluation - the REDUCTION trial
针对老年女性尿路感染症状的文化导向方法的随机试验和可行性研究:混合方法评估 - REDUCTION 试验
- 批准号:
10586250 - 财政年份:2023
- 资助金额:
$ 12.18万 - 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 12.18万 - 项目类别:
Optimizing Time-Limited Trials of Mechanical Ventilation in Acute Respiratory Failure: A Mixed Methods Observational Study
优化急性呼吸衰竭机械通气的限时试验:混合方法观察研究
- 批准号:
10633823 - 财政年份:2023
- 资助金额:
$ 12.18万 - 项目类别: